Ception Report issue

Contributed to NME For profit Phase 3
Founded: Malvern PA United States (2004)
Status: Acquired by Cephalon (2010) → now Teva (2011)

Organization Overview

First Clinical Trial
2008
NCT00538434
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ception Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (2)

reslizumab (cinqair) (3 trials)

sodium chloride (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Eosinophilic Esophagitis (Phase 3)

Esophagitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2